ANIP
Ani Pharmaceuticals Stock Analysis
AI Rating
- Quality7/10
- Growth↑ 9/10
- Value↑ 6/10
ANIP Growth
- Revenue Y/Y↑ 43.78%
- EPS Y/Y↑ 436.54%
- FCF Y/Y↑ 179.61%
ANIP Profitability
- Gross margin ↑ 61.40%
- EPS margin↓ 8.70%
- ROIC 5Y↓ 4.83%
ANIP Risk
- Debt / Equity↓ 1.1
- Debt / FCF↓ 1.9
- Interest coverage↑ 5.8
Ani Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Good risk rating.